Ohio Senate Committee Reviews Bill Requiring In-Person Visits for High-Risk Medications
Ohio House bill requiring in-person visits for “high-risk” medications moves to Senate committee, with advocates concerned about potential abortion pill restrictions.
COLUMBUS, OHIO — An Ohio House bill requiring in-person medical appointments for certain “high-risk” medications is under review by a Senate committee, raising concerns from advocates who see it as an indirect attack on abortion pill access.
Ohio House Bill 324, sponsored by state Rep. Adam Mathews, R-Lebanon, passed the Ohio House in November along party lines with a vote of 60 to 28. The legislation aims to create “greater oversight” over medications with “a high risk of severe adverse effects,” according to Mathews.
Medication Classification Criteria
Under the proposed legislation, medications would require in-person appointments and face mail-order restrictions if they cause complications requiring hospitalization, organ failure, or death in more than 5% of users. The determination would be based on insurance claims data, patient reporting, and data from the Food and Drug Administration.
“The rise of mail-order medication and telehealth has transformed how Ohioans access prescription and over-the-counter drugs,” Mathews told the Ohio Senate Health Committee. “While telehealth often is beneficial, offering increased access to care and convenience, it may fall short when high-risk medications are involved.”
Co-Sponsor Emphasizes Safety Concerns
The measure’s co-sponsor, state Rep. Meredith Craig, R-Smithville, said requiring in-person consultations and banning mail-order sales of “dangerous drugs” through the bill “protects Ohio’s citizens from the risks associated with inadequate oversight in mail-order and telehealth systems.”
The bill does not specifically name any particular medications but would apply to any drugs meeting the 5% threshold for severe complications. Advocates have expressed concern that the legislation could be used to restrict access to mifepristone and other abortion medications, which are currently available through telehealth consultations and mail delivery under federal regulations.
Federal Context on Abortion Medication Access
The timing of the Ohio legislation comes as telehealth access to abortion medication continues under current U.S. Food and Drug Administration rules. The Supreme Court ruled earlier this month that such access can continue according to existing federal regulations.
The bill represents the latest effort by Republican lawmakers to create additional restrictions around medication access, particularly as telehealth services have expanded significantly in recent years. Critics argue the 5% threshold could be applied broadly to limit various medications beyond those used for abortion procedures.
The Senate Health Committee will continue reviewing the legislation as part of the normal committee process. If approved by the Senate, the bill would need to be signed by the governor to become law.
